Edap TMSFOCL +1.91%53 EBITDA Margin % is -36.32% as of Mar. 2026. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 119 Medical Distribution companies, Edap TMS ranks worse than 94.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Edap TMS's EBITDA for the
three
months ended in Mar. 2026 was $-6.5 Mil. Edap TMS's Revenue for the
three
months ended in Mar. 2026 was $17.8 Mil. Therefore, Edap TMS's EBITDA margin for the quarter that ended in Mar. 2026 was -36.32%.
Edap TMS (NAS:FOCL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Edap TMS EBITDA Margin % Related Terms
Edap TMS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Edap TMS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Edap TMS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Edap TMS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (FOCL) has a EBITDA Margin % of -36.32% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #112 out of 119 companies in the Medical Distribution industry, placing it in the top 94.1%.
Is Edap TMS's EBITDA Margin % too high?
Edap TMS's current EBITDA Margin % is -36.32%. Based on the distribution chart, Edap TMS ranks #112 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's EBITDA Margin % compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #112 out of 119 companies for EBITDA Margin %. This places Edap TMS in the lower half of its industry. The industry median EBITDA Margin % is 4.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current EBITDA Margin % is -36.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current EBITDA Margin % is -36.32%. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Edap TMS (FOCL), the current EBITDA Margin % is -36.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52.
GuruFocus considers Edap TMS to be Modestly Overvalued.
Key valuation signals for FOCL:
EBITDA Margin %: -36.32%
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
53GF Score
Get the complete analysis for FOCL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
